VSTM

Verastem, Inc. Press Releases

$9.77
*  
0.22
2.2%
Get VSTM Alerts
*Delayed - data as of Apr. 17, 2015  -  Find a broker to begin trading VSTM now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Gelesis Closes $22M Equity Financing
3/26/2015 9:00:00 AM - PR Newswire




Verastem Reports Year-End 2014 Financial Results
3/10/2015 7:00:00 AM - Business Wire


Verastem to Present at 27th Annual ROTH Conference
3/3/2015 7:00:00 AM - Business Wire






Verastem Announces the Grant of Inducement Awards
2/5/2015 7:00:00 AM - Business Wire


Verastem to Present at Upcoming Investor Conferences
2/3/2015 7:00:00 AM - Business Wire




Verastem Announces Pricing of Public Offering of Common Stock
1/22/2015 8:43:00 PM - Business Wire
▲39.57 % Price Change since this news event. The Volume Ratio is 6.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Verastem Announces Proposed Public Offering of Common Stock
1/20/2015 4:01:00 PM - Business Wire
▲10.65 % Price Change since this news event. The Volume Ratio is 1.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
1/20/2015 8:00:00 AM - Business Wire
▲15.90 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


NovaBay Expands Sales Force for Avenova
1/20/2015 7:00:00 AM - Business Wire


Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma
1/20/2015 7:00:00 AM - Business Wire
▲15.90 % Price Change since this news event. The Volume Ratio is 0.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day